Prostaglandin E2 alteration in contraceptive consumers: as a risk factor for inflammatory diseases
- Authors
- Type
- Published Article
- Journal
- Archives of Gynecology and Obstetrics
- Publisher
- Springer-Verlag
- Publication Date
- Dec 09, 2012
- Volume
- 287
- Issue
- 5
- Pages
- 1031–1037
- Identifiers
- DOI: 10.1007/s00404-012-2661-3
- Source
- Springer Nature
- Keywords
- License
- Yellow
Abstract
PurposeThe aim of this study was to evaluate the effect of oral combined contraceptive pills on Prostaglandin E2 levels and lipid profiles.MethodsThe enzyme-linked immune absorbent assay method and spectrophotometric assay were used for the evaluation of PGE2 levels and lipid profiles, respectively, in 50 healthy women with normal menstrual cycles who served as the control group and 50 women taking contraceptive pill.ResultsThe data obtained for serum Prostaglandin E2, LDL-C, and cholesterol concentrations in contraceptive pill consumers were significantly upper (P = 0.04, 0.002, and 0.05, respectively) than control group. The age of contraceptive pill consumption and the duration of pill intake beyond 36 months had no significant effect on the prostaglandin E2 concentration.ConclusionIt is suggested that the increase of Prostaglandin E2 and atherogenic lipid levels may be related to their probable effects in response to various pathological and physiological properties of COCs.